Exopharm Limited
ASX: EX1.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Sidney Taubenfeld R.Ph
- Employees
- 50
- Headquarters
- Melbourne, Australia
- IPO year
- 2018
- Market cap
- A$1.9M
- Website
- https://www.exopharm.com
Loading EX1…
Loading profile data…Frequently asked questions about EX1
What does Exopharm Limited (EX1.AX) do?
Exopharm Limited, a clinical-stage company, develops transformative medicines based upon extracellular vesicles (EVs) in Australia. The company's technology includes extracellular vesicle positioning system that allows specific molecules to be attached to the surface of exosomes to guide them to target tissues or cell types; leveraging oligonucl...
Where does EX1.AX trade?
Exopharm Limited (EX1.AX) trades on the Australian Securities Exchange.
What sector is EX1.AX in?
Exopharm Limited (EX1.AX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Exopharm Limited?
Sidney Taubenfeld R.Ph is the chief executive officer of Exopharm Limited (EX1.AX).
Where is Exopharm Limited headquartered?
Exopharm Limited is headquartered in Australia.
Does EX1.AX pay a dividend?
Exopharm Limited (EX1.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did EX1.AX go public?
Exopharm Limited (EX1.AX) completed its initial public offering in 2018.